Unlock instant, AI-driven research and patent intelligence for your innovation.

Drug carrier with chelating compound micelles and its application

A compound microcell and chelating technology, which is applied in the direction of non-active ingredient medical preparations, drug combinations, drug delivery, etc., can solve the problems of inability to form microcells, increase costs, etc., and achieve the effect of good fluid dispersion

Active Publication Date: 2016-10-26
ORIGINAL BIOMEDICALS
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of electrostatic adsorption of drugs also has its limitations. The molecular weight is too small or the water-soluble drugs are easily replaced. Like ion exchange resins, it is impossible to form the nucleus of microcells.
Another way is to directly bond drugs, especially metal-containing drugs, such as Cisplatin (cisplatin), Carboplatin (carboplatin), Oxaliplatin (oxaliplatin), etc. However, since these metal-containing drugs are in This is used as a Lewis acid. The functional group of the drug has been replaced after the ligand is bonded to the platinum Pt, which is not the original drug structure. Therefore, the safety and effectiveness of the drug must be re-verified, which may lead to a substantial increase in cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug carrier with chelating compound micelles and its application
  • Drug carrier with chelating compound micelles and its application
  • Drug carrier with chelating compound micelles and its application

Examples

Experimental program
Comparison scheme
Effect test

no. 1 example

[0034] According to a first embodiment of the present invention, the present invention provides a kind of chelating composite micelles as drug carrier, and the chelating composite micelles further comprise a metal ion core and at least one ligand (ligands), the metal ion core It is used as a Lewis acid (Lewisacid) and binds ligands (ligands) by a coordinate bond, which is selected from one of the following groups or any combination thereof or derivatives thereof: iron Fe, copper Cu, nickel Ni, Indium In, Calcium Ca, Cobalt Co, Chromium Cr, Gadolinium Gd, Aluminum Al, Tin Sn, Zinc Zn, Tungsten W, Scandium Sc, Titanium Ti, Manganese Mn, Vanadium V, Magnesium Mg, Beryllium Be, Lanthanum La, Gold Au, silver Ag, cadmium Cd, mercury Hg, palladium Pd, rhenium Re, cesium Tc, cesium Cs, radium Ra, iridium Ir, gallium Ga, and the composition of ligands (ligands) 120 is selected from one of the following groups Or any combination or derivative thereof: carboxylic acids, alcohols, ketones...

no. 3 example

[0039]According to a third embodiment of the present invention, the present invention provides a pharmaceutical composition with chelated complex micelles, such as: a cytoprotective agent, and the pharmaceutical composition with chelated composite micelles further includes a metal ion core , at least one block copolymer (blockcopolymer) and the drug, wherein the metal ion core is used as a Lewis acid (Lewis acid), and at least one block copolymer (block copolymer) and the drug are both used as a Lewis base (Lewis base), And the electron pair provided by the Lewis base enables the metal ion core to form a coordination bond with the block copolymer (blockcopolymer) and the drug.

[0040] The above-mentioned metal ion core further includes an Fe iron ion or Gd gadolinium ion, and the above-mentioned drug further includes Amifostine, WR-1065, and the above-mentioned block copolymer further includes a chelating end that can interact with iron ions. Bonding, the other end is a dispe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
concentrationaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention provides a chelating compound microcell applied to a drug carrier. The chelating compound microcell of the invention can bond without destroying or changing the drug structure, and prolongs the half-life of the drug in the human body.

Description

technical field [0001] The present invention relates to a drug carrier, in particular to a drug carrier with chelated complex micelles and its formulation and formation method. Background technique [0002] The side effects caused by radiation therapy and chemotherapy are well known to cancer patients, and the toxicity of anticancer drugs has always been criticized by patients, because severe side effects will cause secondary damage and greater dreams for many cancer patients Difficult; If the patient cannot complete the scheduled course of treatment due to the serious side effects caused by radiation therapy and chemotherapy, not only the curative effect cannot be achieved but also the medical resources will be wasted. Radiation therapy and chemotherapy have no selectivity for normal cells or cancer cells. Therefore, when cancer cells are eliminated, normal cells also suffer. Patients often suffer from oral ulcers, loss of appetite, diarrhea, hair loss, and white blood cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/48
CPCA61K49/1809A61K51/1227A61K9/1075A61K9/5115A61K9/5153A61K47/60A61K47/547A61K47/645A61K47/6907A61P35/00A61P39/00A61P39/02A61K9/107A61K9/127A61K33/24
Inventor 王朝晖陈嘉宏林炯森陈静仪廖伟全
Owner ORIGINAL BIOMEDICALS